Beta Drugs Ltd

- Current CAPEX already incurred is around Rs.18-19 crores (Rs.7.5 crores building, Rs.11.5 crores machinery). - No major CAPEX planned except adding one line in API for new GMP. - Company has enough reserves for CAPEX; may borrow 1-2 crores from bank if needed but is largely self-reliant. - Cash and cash equivalents exceed outside borrowings by at least Rs.1 crore, indicating no immediate debt raising. - No mention of any current or near-term equity fundraising in the call. - Focus is on internal accruals and maintaining low-cost finance (CFO’s bandwidth includes getting lowest interest rate and maximizing cash reserves). - Overall, Beta Drugs does not currently plan major new fundraising through debt or equity beyond minor bank borrowing for CAPEX if required.

- Beta Drugs has incurred CAPEX of around Rs.18-19 crores recently (Rs.7.5 crores in building, Rs.11.5 crores in machinery). - Planned CAPEX mainly includes adding one new API line for new GMP compliance. - Additional CAPEX requirements are minimal; the company is largely self-reliant with enough reserves. - If needed, a small amount (1-2 crores) may be borrowed from banks. - Expansion plans include acquisition of land approved for manufacturing intermediates, multiple blocks, new formulation plant, and new API plant. - Work on the new land and expansion has already started. - Overall strategy includes steady CAPEX to support growth, targeting turnover of Rs.300-350 crores from current capacities. - Focus on backward integration and capacity enhancement, including increasing lyophilized injectable capacity by threefold. This summarizes current and near-term capital investment plans discussed.

- Beta Drugs Limited targets a consistent revenue growth of around 30% annually for the next 3-4 years. - Growth will be driven by strong organic growth in domestic markets, new product launches, and export market expansion. - Exports contribution expected to rise from current low levels to around 30%-35% in the next 3-4 years, focusing on regulated developing markets like Latin America, CIS, and Southeast Asia. - CRAMS (contract manufacturing) revenue share is expected to reduce in proportion but will still grow in absolute terms. - Domestic market growth expected through penetration in tier-2 and tier-3 cities and expansion in hospital tie-ups. - Revenue generation potential from current capacity is Rs.300-350 crores with leverage of 40%-70% in existing facilities. - EBITDA margins expected to improve, possibly reaching 26%-27% in 3-4 years aided by export market growth. - New product pipeline includes 35 molecules planned for launch by 2025, maintaining continuous product flow.

- Revenue growth guidance of 30% annually for the next 3-4 years (Page 6). - EBITDA margin expected to improve by 100 basis points in FY22-23 from 24% to 24.5%, targeting 26-27% margins in 3-4 years (Page 6). - Net profit increased by 112% in FY22 already, signaling strong earnings momentum (Page 2). - EBITDA margin expansion driven by higher sales of own brands, exports, and cost realizations (Page 2). - Further margin improvement expected from increased penetration in international markets which have higher price realization (Page 6). - Continued focus on new product launches, market penetration especially in domestic and regulated markets supports sustained earnings growth (Pages 5, 10). - Expectation of capital expenditure being self-reliant with minimal external funding, supporting controlled costs (Page 14).

- The transcript does not explicitly mention the current or expected orderbook or pending orders in exact figures. - Rahul Batra emphasizes a large and aggressive product development pipeline with 35 new molecules planned by 2025. - The company is focused on launching 8-12 molecules by 2023-24, indicating strong future order potential. - There is an ongoing effort to build international client relationships, especially in CIS countries and exports, suggesting growing order inflow over the next few years. - Capacity utilization shows levers: 60%-70% available for oral facility and 40%-50% for injectable (lyophilizers), indicating room to handle increased orders. - Overall, a clear roadmap is in place for 30% annual growth with expanding domestic and export markets, implying steady and growing order flow ahead.